Study S000411

Effect of Tirzepatide on Energy Intake and Appetite-and Reward-Related Brain Areas in Overweight/Obese Subjects: A Placebo-Controlled 6-Week Study With Functional MRI

Included trial: extracted data ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT04311411
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 114
Start: 2020-08-24
Primary completion: 2022-12-16
Lead sponsor: Eli Lilly and Company
Conditions: Obesity; Overweight
Interventions: DRUG:Tirzepatide; DRUG:Placebo; DRUG:Liraglutide
Results posted: TRUE
Individual participant data sharing: NO
Secondary identifiers: OTHER:I8F-MC-GPHH

Registered primary outcomes

Change From Baseline in Calorie Intake in Participants Receiving Tirzepatide or Placebo at Week 3 [Baseline, Week 3]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0012789	Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Martin CK, Nature medicine	2025	Randomized trial	PMID 40555748 DOI	cites ClinicalTrials.gov:NCT04311411; registry reference DERIVED:40555748